UFT	O
and	O
its	O
metabolites	O
inhibit	O
the	O
angiogenesis	O
induced	O
by	O
murine	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
,	O
as	O
determined	O
by	O
a	O
dorsal	B-Multi-tissue_structure
air	I-Multi-tissue_structure
sac	I-Multi-tissue_structure
assay	O
in	O
mice	O
.	O

UFT	O
,	O
an	O
anticancer	B-Cancer
agent	O
that	O
is	O
composed	O
of	O
tegafur	O
(	O
FT	O
)	O
and	O
uracil	O
at	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
4	O
,	O
is	O
widely	O
used	O
in	O
clinical	O
practice	O
in	O
Japan	O
to	O
treat	O
cancer	B-Cancer
patients	O
requiring	O
a	O
long	O
-	O
term	O
chemotherapy	O
,	O
and	O
it	O
is	O
associated	O
with	O
few	O
side	O
effects	O
,	O
if	O
any	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
inhibitory	O
effect	O
of	O
UFT	O
against	O
RENCA	B-Cell
cell	I-Cell
-	O
induced	O
angiogenesis	O
by	O
a	O
dorsal	B-Multi-tissue_structure
air	I-Multi-tissue_structure
sac	I-Multi-tissue_structure
assay	O
.	O

Marked	O
angiogenesis	O
is	O
induced	O
by	O
implantation	O
of	O
a	O
chamber	O
containing	O
RENCA	B-Cell
cells	I-Cell
into	O
mice	O
.	O

In	O
this	O
model	O
,	O
UFT	O
showed	O
a	O
strong	O
angiogenesis	O
-	O
inhibitory	O
effect	O
,	O
whereas	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
doxifluridine	O
were	O
less	O
effective	O
.	O

Additional	O
experiments	O
revealed	O
FT	O
to	O
be	O
effective	O
component	O
of	O
UFT	O
;	O
uracil	O
remained	O
ineffective	O
in	O
the	O
inhibition	O
of	O
angiogenesis	O
.	O

Moreover	O
,	O
we	O
have	O
found	O
that	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
the	O
metabolites	O
of	O
FT	O
,	O
possess	O
a	O
potent	O
angiogenesis	O
inhibitory	O
effect	O
that	O
is	O
amplified	O
when	O
the	O
compounds	O
are	O
administered	O
by	O
a	O
continuous	O
infusion	O
.	O

This	O
may	O
reflect	O
a	O
transition	O
in	O
blood	B-Organism_substance
concentration	O
of	O
each	O
metabolite	O
resulting	O
from	O
the	O
administration	O
of	O
UFT	O
.	O

Similar	O
results	O
were	O
also	O
obtained	O
with	O
respect	O
to	O
5	O
-	O
FU	O
.	O

It	O
was	O
suggested	O
that	O
UFT	O
has	O
a	O
stronger	O
angiogenesis	O
-	O
inhibitory	O
effect	O
than	O
did	O
other	O
fluorinated	O
pyrimidines	O
,	O
partly	O
due	O
to	O
its	O
pharmacokinetic	O
properties	O
characterized	O
by	O
maintaining	O
of	O
higher	O
and	O
long	O
-	O
lasting	O
blood	B-Organism_substance
levels	O
of	O
5	O
-	O
FU	O
and	O
partly	O
due	O
the	O
inhibitory	O
effects	O
derived	O
from	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
UFT	O
-	O
specific	O
metabolites	O
.	O

